Do not let electrode fouling be the enemy of bioanalysis

Electrochemical biosensors are one of the best choices for the sensing of biomarkers due to their high performance, low cost, miniaturization, and wide applicability. However, like for any sensing process, electrode fouling affects severely the analytical performance of the sensor, such as sensitivity, detection limit, reproducibility, and overall reliability. Fouling arises from nonspecific adsorption of different components present in the sensing medium and in particular in complex biofluids such as full blood.

The complex composition of blood where biomarkers are present at extremely low concentrations compared to the rest of the fluid composition makes electrochemical biosensing challenging. Direct biomarker analysis within full blood samples remains however central for the future development in electrochemical-based diagnostics. Herein, we aim to provide short discussion of past and more recent strategies and concepts employed to diminish background noise due to surface fouling and overcome current hurdles for the implementation and commercialisation of electrochemical-based biosensors for medical diagnostics of protein biomarkers in a point of care format.

Read full article here


Healthcare: what are the benefits of wearable devices?

Strong transformations have happened in recent years. Covid outbreak had a tremendous impact on our lives and our practices, encouraging and accelerating technological and social changes at many levels. Most obvious is of course teleworking and home delivery as response to lock down and travel restrictions, but it has also modified our perception of medical innovations that was already happening in healthcare, all looking after the same objective: avoid unnecessary visits to hospital and physicians to reduce occupation and face medical staff reduction.

Markets are already moving on with these technologies. United States before anyone else, followed by Europe and Asia Pacific region. This is directly linked to the fact these regions are facing an ageing population with the challenge related to chronic diseases, and an increased awareness of infectious diseases.

All-in-all, the benefits of the new wearable “smart-patches” are multiple and significant. Alix Joseph, New Ventures HealthCare Director at Linxens have listed 5 major benefits to both clinicians, patients and society:

1. Continuous monitoring: Unlocking easy continuous monitoring of various physiological parameters such as heartbeat, temperature or breathing (but not only), it provides a complete picture of patients’ vital signs, not only a snapshot.
2. Remote monitoring: Connected to smartphones or other devices, they allow patients to send data to healthcare providers remotely. This can help to identify problems early and improve the management of chronic conditions.
3. Early detection: Continuous monitoring allows for early detection of changes in patients’ health leads to early treatment and then better outcomes.
4. Personalized medicine: Monitoring and tracking individual patients’ health metrics, providing valuable information could be used to develop personalized treatment plans.
5. Cost-effective: Being disposable and less expensive than other traditional medical devices and lab tests, it makes them more accessible for patients and healthcare providers.

Linxens is working on the vertical integration of the different pieces in these wearable medical devices to ensure the easier and faster development, focusing on robust and reliable solutions. The expertise gained in the past decades in mass production for flexible electronics leads to a unique capacity to propose cost-effective complex solutions for medical partners, both for biosensors, design, converting and secured data transfer.

If you wish to discuss with Alix Joseph, New Ventures HealthCare Director at Linxens, do not hesitate to contact us.

Press contact : Agence Elektron

Alicja Prod’homme / +33 6 50 17 54 91 /
Camille Gachet / +33 6 84 34 74 70 /


RFID: The future of smart labelling?

Are cloud-based registries that use radio frequency identification (RFID) to track drug supply truly providing a value-add compared with other alternatives?

The pharmaceutical industry began using radio frequency identification (RFID) tags in the early 2000s. Pfizer was the first to use the tech, adding RFID tags to track a Viagra (sildenafil)  shipment circa 2006. Various uses soon became apparent including those for supply chain management, anti-counterfeiting, and to improve patient safety.

Read more in full article here